How Viable Is The Future Of The “Traditional” CGM?
Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.
You may also be interested in...
Movano expects to introduce its first smart ring, this one specifically for women, in the first half of 2023 in the US while it continues clinical trials to add medical parameters requiring FDA clearances, such as glucose and blood pressure.
In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.
Less than a month after it sold off its reproductive health assets, Invitae has filed for bankruptcy. That will not come as a surprise to anyone following the company.